BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $15.17.

Several research analysts recently commented on the company. Barclays lifted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Evercore ISI raised their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th.

BioCryst Pharmaceuticals Stock Up 0.1 %

Shares of BCRX opened at $7.62 on Thursday. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -12.49 and a beta of 1.76. The business has a 50-day simple moving average of $7.55 and a two-hundred day simple moving average of $7.64.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same period in the prior year, the business earned ($0.19) earnings per share. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. On average, equities analysts anticipate that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C lifted its stake in BioCryst Pharmaceuticals by 62.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after purchasing an additional 3,140,804 shares in the last quarter. Geode Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after purchasing an additional 127,708 shares during the period. Fisher Asset Management LLC lifted its stake in BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares during the last quarter. Two Sigma Advisers LP raised its stake in BioCryst Pharmaceuticals by 13.6% in the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after buying an additional 261,500 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in shares of BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after buying an additional 84,102 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.